The Symetria Health® leadership team pioneered the breakthrough treatment methods and medications utilized to deliver the most successful outcomes.
Chris Hassan, Chief Executive Officer
Chris Hassan is a senior healthcare executive with over 25 years of experience in the field of addiction treatment. He is the President and CEO of Symetria Health®, the country’s first comprehensive evidence-based opioid addiction treatment program, designed to deliver data-validated outcomes that outperform other treatments currently available.
Prior to joining Symetria Health®, Chris co-founded Reckitt Benckiser Pharmaceuticals creating the office-based treatment model for opioid dependence and launching Suboxone®. Subsequently, he served as Chief Executive Officer of Colonial Management Group – the largest chain of opioid addiction treatment centers in the US at the time. He also developed and patented several new opioid product combinations focused on preventing diversion and inadvertent benzodiazepine overdose in patients.
Chris is active on several national panels and corporate boards while also serving as a Huffington Post contributor.
Tim Bohman, Chief Operating Officer
As Symetria Health®’s Chief Operating Officer, Tim Bohman is responsible for planning and implementing the company’s policies and objectives; executing growth strategies, including new program development; overseeing the efficiency and effectiveness of patient services; as well as managing the marketing and outreach efforts for the organization.
Tim has over 20 years of experience working with opioid treatment programs and clinics. His past experience includes Clinic Director for Lewin Clinics, Director of Development and Regional Director for National Specialty Clinics and, most recently, as Regional Vice President for Acadia Healthcare and CRC Health Group before it was acquired by Acadia. In his previous roles, Tim has fostered key relationships with regulators and legislators at both the state and national level, working with lobbyists to introduce legislative initiatives and defending best practices in addiction treatment. Tim is also the past president of INTOD, Indiana’s OTP provider association and was a former board member of AATOD.
Martyn Gibson, Chief Financial Officer
As Symetria Health®’s Chief Financial Officer, Martyn Gibson is responsible for all aspects of finance and accounting, IS infrastructure, strategic planning and forecasting, revenue and cash flow management.
Martyn joined Symetria following 12 years with Reckitt Benckiser Pharmaceuticals supporting the commercialization and manufacturing of Suboxone®, Subutex® and Buprenex®. Martyn served as Global Head of Finance for the division, with responsibilities that included strategic planning, supply chain management and IS as part of the founding commercial leadership team. Martyn has consulted with several leading companies and brands within the substance use disorder treatment segment. He has Fellowship designation from the Association of Chartered Certified Accountants (ACCA) and has been an Honorary Board Member and Treasurer of a non-profit organization offering substance use disorder treatment services since 2008.
Dr. Abid K. Nazeer, M.D., Chief Medical Officer
Dr. Abid Nazeer is board certified in Psychiatry as well as Addiction Medicine. He is a member of the American Society of Addiction Medicine (ASAM). He is also certified in BRIDGE medical device procedures for opiate withdrawal, and has expertise in pharmacogenetic testing and its clinical application.
Dr. Nazeer oversees psychiatric and addiction medicine care at Symetria Recovery®, and is responsible for guiding The Symetria Method® protocol at the company’s network of treatment centers. He manages outpatient medication management for patients with a co-existing psychiatric illness or on medications for psychiatric diagnosis; educates staff and patients on the potential impact unresolved psychiatric symptoms, such as anxiety or depression, can have on the recovery process; and oversees the development of treatment plans for patients with dual diagnosis.
In addition to his CMO role at Symetria Recovery, Dr. Nazeer runs Advanced Psychiatric Solutions, a private practice based in Oak Brook, IL that specializes in interventional psychiatry, treatment resistant depression, and post-traumatic stress disorder (PTSD). He was the first psychiatrist in the state of Illinois to offer IV Ketamine Infusion Therapy in an outpatient clinic setting for the treatment of psychiatric conditions.
Dr. Nazeer is frequently called upon to share his medical expertise with local and national media outlets, and gives educational lectures and presentations regarding opiate and substance use disorders. He has served as medical director for both the Chemical Dependency IOP at Presence Mercy Medical Center (Aurora, IL) and Willis Knighton Addiction Recovery Center (Shreveport, LA), and was a staff psychiatrist at Macneal Hospital (Berwyn, IL) and Advocate Good Samaritan Hospital (Downers Grove, IL). Dr. Nazeer trained and held the role of chief resident at Louisiana State University Shreveport.
Tony Goodman, Executive Vice President, Marketing and Commercial Development
Tony is currently the Executive Vice President, Marketing and Commercial Development, Symetria Health. Prior to this, Tony was the Founder, Keswick Group, LLC, a Healthcare Strategic Commercial and Business Development Advisory Firm. Tony is the former Chief Business Development Officer, Indivior PLC and member of the Executive Team which brought Indivior (INDV) public as a FTSE500 company.
Tony’s career spans +23 years in Pharma and Biotech including Global leadership roles as Head, Commercial Development and Strategic Planning; Head, Category Development; Director, Business Development and US Head, Commercial Managed Care. Earlier roles include Group Product Manager, Marketing; Director of the Managed Health Strategies and Director, Strategic Marketing. Tony holds a BA degree from Marshall University, is currently a Full Board Executive with the National Association of Corporate Directors, and a Board Member at Adial Pharmaceuticals, Inc.